Emergent Biosolutions, Inc. (EBS) Social Stream



Emergent Biosolutions, Inc. (EBS): $30.53

-0.72 (-2.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EBS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Emergent BioSolutions Inc (EBS) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering EBS.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-08 7 $120 $50 $83.666 $43.63 91.76%
2021-11-10 7 $120 $50 $80 $43.63 83.36%
2022-01-18 6 $75 $50 $62.5 $43.63 43.25%
2022-02-25 6 $77 $55 $66.4 $43.63 52.19%
2022-02-28 6 $77 $40 $61 $43.63 39.81%
2022-03-09 6 $77 $40 $60.8 $43.63 39.35%

The Trend in the Analyst Price Target


Over the past 44 weeks, EBS's average price target has gone down $30.34.

EBS reports an average of 58.97% for its upside potential over the past 48 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-04-25 8 150 67 111.14 61.94 79.43%
2021-06-05 9 120 64 91.14 64.40 41.52%
2021-08-01 9 120 63 85.71 65.90 30.06%
2021-08-07 9 120 63 85.71 60.81 40.95%
2022-03-09 6 77 40 60.80 42.20 44.08%

EBS Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2 3 0 3 0 0 6

The Trend in the Broker Recommendations


Over the past 35 weeks, EBS's average broker recommendation rating improved by 0.22.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • In the context of all US stocks, Emergent BioSolutions Inc's variance in analysts' estimates is lower than -412.52% of them.
  • In terms of how Emergent BioSolutions Inc fares relative to Pharmaceutical Products stocks, note that its average analyst price target is higher than 551.06% of that group.
  • In terms of how Emergent BioSolutions Inc fares relative to Pharmaceutical Products stocks, note that its upside potential (average analyst target price relative to current price) is greater than 168.25% of that group.
  • Emergent BioSolutions Inc's number of analysts covering the stock is higher than 299.88% of stocks in the mid market cap category.

In the Pharmaceutical Products industry, DVAX, DCPH, and CYTK are the three stocks most similar to Emergent BioSolutions Inc regarding the price target and analyst recommendation information presented here.

Is EBS a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4291 seconds.